Startseite Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability

  • Andrea Padoan ORCID logo , Renata D’Incà , Maria Luisa Scapellato , Rudi De Bastiani , Roberta Caccaro , Claudia Mescoli , Stefania Moz , Dania Bozzato , Carlo-Federico Zambon , Greta Lorenzon , Massimo Rugge , Mario Plebani ORCID logo und Daniela Basso EMAIL logo
Veröffentlicht/Copyright: 5. Mai 2018
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 56 Heft 11

Abstract

Background:

The appropriate clinical use of fecal calprotectin (fCal) might be compromised by incomplete harmonization between assays and within- and between-subjects variability. Our aim was to investigate the analytical and biological variability of fCal in order to provide tools for interpreting fCal in the clinical setting.

Methods:

Experiments were conducted to investigate the effects of temperature and storage time on fCal. Thirty-nine controls were enrolled to verify biological variability, and a case-control study was conducted on 134 controls and 110 IBD patients to compare the clinical effectiveness of three different fCal assays: ELISA, CLIA and turbidimetry.

Results:

A 12% decline in fCal levels was observed within 24 h following stool collection irrespective of storage temperature. Samples were unstable following a longer storage time interval at room temperature. Within- and between-subjects fCal biological variability, at 31% and 72% respectively, resulted in a reference change value (RCV) in the region of 100%. fCal sensitivity in distinguishing between controls and IBD patients is satisfactory (68%), and the specificity high (93%) among young (<65 years), but not among older (≥65 years) subjects (ROC area: 0.584; 95% CI: 0.399–0.769). Among the young, assays have different optimal thresholds (120 μg/g for ELISA, 50 μg/g for CLIA and 100 μg/g for turbidimetry).

Conclusions:

We recommend a standardized preanalytical protocol for fCal, avoiding storage at room temperature for more than 24 h. Different cutoffs are recommended for different fCal assays. In monitoring, the difference between two consecutive measurements appears clinically significant when higher than 100%, the fCal biological variability-derived RCV.

Keywords: biological variability; calprotectin; Crohn’s disease; inflammatory bowel diseases; ulcerative colitis
Corresponding author: Daniela Basso, MD, Department of Medicine – DIMED, University of Padova, Via Giustiniani 2, 35128 Padova, Italy, Phone: +390498212801, Fax: +390498211981

Acknowledgments

The authors thank Mrs. Monica Razetti and Cinzia Centobene for their valuable technical help in performing the analyses.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: University of Padova, Department of Medicine – DIMED: BIRD173078/17.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571–607.10.1136/gut.2010.224154Suche in Google Scholar PubMed

2. Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology 2015;149:1275–85.e2.10.1053/j.gastro.2015.07.003Suche in Google Scholar PubMed

3. Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006;101:2410–22.10.1111/j.1572-0241.2006.00840.xSuche in Google Scholar PubMed

4. Fengming Y, Jianbing W. Biomarkers of inflammatory bowel disease. Dis Markers 2014;2014:710915.10.1155/2014/710915Suche in Google Scholar PubMed PubMed Central

5. Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015;110:444–54.10.1038/ajg.2015.6Suche in Google Scholar PubMed

6. Lin J-F, Chen J-M, Zuo J-H, Yu A, Xiao ZJ, Deng FH, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014;20:1407–15.10.1097/MIB.0000000000000057Suche in Google Scholar PubMed

7. Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess 2013;17:xv–xix–1–211. [Epub ahead of print] 24286461.10.3310/hta17550Suche in Google Scholar PubMed PubMed Central

8. Kok L, Elias SG, Witteman BJ, Goedhard JG, Muris JW, Moons KG, et al. Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the cost-effectiveness of a decision rule for abdominal complaints in primary care (CEDAR) study. Clin Chem 2012;58:989–98.10.1373/clinchem.2011.177980Suche in Google Scholar PubMed

9. Zubin G, Peter L. Predicting endoscopic Crohn’s disease activity before and after induction therapy in children: a comprehensive assessment of PCDAI, CRP, and fecal calprotectin. Inflamm Bowel Dis 2015;21:1386–91.Suche in Google Scholar

10. Louis E, Mary JY, Massouille GV, Grimaud JC, Bouhnik Y, Laharie D, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after Infliximab therapy is stopped. Gastroenterology 2012;142:63–70.e5.10.1053/j.gastro.2011.09.034Suche in Google Scholar PubMed

11. D’Inca R, Caccaro R. Measuring disease activity in Crohn’s disease: what is currently available to the clinician. Clin Exp Gastroenterol 2014;7:151–61.10.2147/CEG.S41413Suche in Google Scholar PubMed PubMed Central

12. Boschetti G, Garnero P, Moussata D, Cuerq C, Préaudat C, Duclaux-Loras R, et al. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn’s disease. Inflamm Bowel Dis 2015;21:331–6.10.1097/MIB.0000000000000273Suche in Google Scholar

13. Whitehead SJ, French J, Brookes MJ, Ford C, Gama R. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem 2013;50:53–61.10.1258/acb.2012.011272Suche in Google Scholar

14. Lasson A, Stotzer P-O, Öhman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis 2015;9:26–32.10.1016/j.crohns.2014.06.002Suche in Google Scholar

15. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793–8.10.3109/00365529209011186Suche in Google Scholar

16. Husebye E, Tøn H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol 2001;96:2683–7.10.1016/S0002-9270(01)02688-0Suche in Google Scholar

17. Du L, Foshaug R, Huang VW, Kroeker KI, Dieleman LA, Halloran BP, et al. Within-stool and within-day sample variability of fecal calprotectin in patients with inflammatory bowel disease: a prospective observational study. J Clin Gastroenterol 2018;52:235–40.10.1097/MCG.0000000000000776Suche in Google Scholar PubMed

18. Calafat M, Cabré E, Mañosa M, Lobatón T, Marín L, Domènech E. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? Inflamm Bowel Dis 2015;21:1072–6.10.1097/MIB.0000000000000349Suche in Google Scholar PubMed

19. Plebani M. What information on quality specifications should be communicated to clinicians, and how? Clin Chim Acta 2004;346:25–35.10.1016/j.cccn.2004.03.019Suche in Google Scholar PubMed

20. De Sloovere MM, De Smet D, Baert FJ, Debrabandere J, Vanpoucke HJ. Analytical and diagnostic performance of two automated fecal calprotectin immunoassays for detection of inflammatory bowel disease. Clin Chem Lab Med 2017;55:1435–46.10.1515/cclm-2016-0796Suche in Google Scholar PubMed

21. Kittanakom S, Shajib MS, Garvie K, Turner J, Brooks D, Odeh S, et al. Comparison of fecal calprotectin methods for predicting relapse of pediatric inflammatory bowel disease. Can J Gastroenterol Hepatol 2017;2017:1450970.10.1155/2017/1450970Suche in Google Scholar PubMed PubMed Central

22. Clinical and Laboratory Standards Institute (CLSI). User verification of precision and estimation of bias; Approved Guideline—Third Edition. CLSI EP15, Wayne, PA, USA, 2014.Suche in Google Scholar

23. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409–37.10.3109/10408368909106595Suche in Google Scholar PubMed

24. van Deen WK, van Oijen MG, Myers KD, Centeno A, Howard W, Choi JM, et al. A nationwide 2010-2012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis 2014;20:1747–53.10.1097/MIB.0000000000000139Suche in Google Scholar PubMed

25. Ferreiro-Iglesias R, Barreiro-de Acosta M, Lorenzo-Gonzalez A, Dominguez-Muñoz JE. Accuracy of consecutive fecal calprotectin measurements to predict relapse in inflammatory bowel disease patients under maintenance with anti-TNF therapy: a prospective longitudinal cohort study. J Clin Gastroenterol 2018;52:229–34.10.1097/MCG.0000000000000774Suche in Google Scholar PubMed

26. Heida A, Park KT, van Rheenen PF. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: a systematic review and practical guide. Inflamm Bowel Dis 2017;23:894–902.10.1097/MIB.0000000000001082Suche in Google Scholar PubMed PubMed Central

27. Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. Scand J Gastroenterol 2013;48:1048–54.10.3109/00365521.2013.816771Suche in Google Scholar PubMed

28. Schoepfer AM, Lewis JD. Serial fecal calprotectin measurements to detect endoscopic recurrence in postoperative Crohn’s disease: is colonoscopic surveillance no longer needed? Gastroenterology 2015;148:889–92.10.1053/j.gastro.2015.03.022Suche in Google Scholar PubMed

29. Bjarnason I. The use of fecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2017;13:53–6.Suche in Google Scholar

30. Dumoulin EN, Van Biervliet S, Langlois MR, Delanghe JR. Proteolysis is a confounding factor in the interpretation of faecal calprotectin. Clin Chem Lab Med 2015;53:65–71.10.1515/cclm-2014-0568Suche in Google Scholar PubMed

31. Hayden JA, Brophy MB, Cunden LS, Nolan EM. High-affinity manganese coordination by human calprotectin is calcium-dependent and requires the histidine-rich site formed at the dimer interface. J Am Chem Soc 2013;135:775–87.10.1021/ja3096416Suche in Google Scholar PubMed PubMed Central

32. Annaházi A, Molnár T, Farkas K, Rosztóczy A, Izbéki F, Gecse K, et al. Fecal MMP-9: a new noninvasive differential diagnostic and activity marker in ulcerative colitis. Inflamm Bowel Dis 2013;19:316–20.10.1002/ibd.22996Suche in Google Scholar PubMed

33. Farkas K, Saródi Z, Bálint A, Földesi I, Tiszlavicz L, Szűcs M, et al. The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases. J Crohns Colitis 2015;9:231–7.10.1093/ecco-jcc/jjv005Suche in Google Scholar PubMed

34. Farkas K, Bálint A, Bor R, Földesi I, Szűcs M, Nagy F, et al. Faecal matrix metalloprotease-9 is a more sensitive marker for diagnosing pouchitis than faecal calprotectin: results from a pilot study. Expert Rev Gastroenterol Hepatol 2015;9: 387–92.10.1586/17474124.2015.965144Suche in Google Scholar PubMed

35. Moz S, Basso D, Padoan A, Bozzato D, Fogar P, Zambon CF, et al. Blood expression of matrix metalloproteinases 8 and 9 and of their inducers S100A8 and S100A9 supports diagnosis and prognosis of PDAC-associated diabetes mellitus. Clin Chim Acta 2016;456:24–30.10.1016/j.cca.2016.02.018Suche in Google Scholar PubMed

36. Basso D, Bozzato D, Padoan A, Moz S, Zambon CF, Fogar P, et al. Inflammation and pancreatic cancer: molecular and functional interactions between S100A8, S100A9, NT-S100A8 and TGFβ1. Cell Commun Signal 2014;12:20.10.1186/1478-811X-12-20Suche in Google Scholar PubMed PubMed Central

37. Joshi S, Lewis SJ, Creanor S, Ayling RM. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem 2010;47:259–63.10.1258/acb.2009.009061Suche in Google Scholar PubMed

Supplementary Material:

The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2018-0134).

Received: 2018-02-05
Accepted: 2018-04-03
Published Online: 2018-05-05
Published in Print: 2018-10-25

©2018 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. New biomarkers and traditional cardiovascular risk scores: any crystal ball for current effective advice and future exact prediction?
  4. Reviews
  5. Laboratory sample stability. Is it possible to define a consensus stability function? An example of five blood magnitudes
  6. Updated review of postmortem biochemical exploration of hypothermia with a presentation of standard strategy of sampling and analyses
  7. Long non-coding RNA-mediated regulation of signaling pathways in gastric cancer
  8. Opinion Paper
  9. Long story short: an introduction to the short-term and longterm Six Sigma quality and its importance in laboratory medicine for the management of extra-analytical processes
  10. EFLM Paper
  11. The European Federation of Clinical Chemistry and Laboratory Medicine syllabus for postgraduate education and training for Specialists in Laboratory Medicine: version 5 – 2018
  12. General Clinical Chemistry and Laboratory Medicine
  13. Early availability of laboratory results increases same day ward discharge rates
  14. Evaluation of the clinical implementation of a large-scale online e-learning program on venous blood specimen collection guideline practices
  15. Improved prospective risk analysis for clinical laboratories compensated for the throughput in processes
  16. National surveys on internal quality control for blood gas analysis and related electrolytes in clinical laboratories of China
  17. Clinical validation of S100B in the management of a mild traumatic brain injury: issues from an interventional cohort of 1449 adult patients
  18. A quantitative LC-MS/MS method for insulin-like growth factor 1 in human plasma
  19. Development and validation of a mass spectrometry-based assay for quantification of insulin-like factor 3 in human serum
  20. Anti-ganglioside antibodies: experience from the Italian Association of Neuroimmunology external quality assessment scheme
  21. Reference Values and Biological Variations
  22. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability
  23. Establishing normal values of total testosterone in adult healthy men by the use of four immunometric methods and liquid chromatography-mass spectrometry
  24. Cancer Diagnostics
  25. Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases
  26. Cardiovascular Diseases
  27. Prognostic implications of detectable cardiac troponin I below the 99th percentile in patients admitted to an emergency department without acute coronary syndrome
  28. Osteocalcin value to identify subclinical atherosclerosis over atherosclerotic cardiovascular disease (ASCVD) risk score in middle-aged and elderly Chinese asymptomatic men
  29. Infectious Diseases
  30. Comparison of four methods of establishing control limits for monitoring quality controls in infectious disease serology testing
  31. Letter to the Editor
  32. Letter to the Editor relative to Clin Chem Lab Med 2018;56(3):360–372
  33. Update in diagnosis and management of primary aldosteronism: reply to a Letter to the Editor
  34. Can calculated total nitrogen replace Kjeldahl total nitrogen measurements in 24-h urine samples?
  35. Analytical performance of the single well titer function of NOVA View®: good enough to omit ANA IIF titer analysis?
  36. Assessment of Architect cSystems Abbott® for the colorimetric measurement of lithium in urines and dyalisates
  37. β-Trace protein in hemodialysis – comparison of different therapy modalities and high flux dialyzers
  38. Orbitrap™ high-resolution mass spectrometry for the identification of amoxicillin crystalluria
  39. High fluorescence cell count in ascitic body fluids for carcinomatosis screening
  40. The International Society for Enzymology: a glorious history, a golden legacy
  41. Congress Abstracts
  42. 10th National Congress of the Portuguese Society of Clinical Chemistry, Genetics and Laboratory Medicine
  43. 5th EFLM-UEMS European Joint Congress in Laboratory Medicine
https://doi.org/10.1515/cclm-2018-0134
Schlagwörter für diesen Artikel
biological variability; calprotectin; Crohn’s disease; inflammatory bowel diseases; ulcerative colitis

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. New biomarkers and traditional cardiovascular risk scores: any crystal ball for current effective advice and future exact prediction?
  4. Reviews
  5. Laboratory sample stability. Is it possible to define a consensus stability function? An example of five blood magnitudes
  6. Updated review of postmortem biochemical exploration of hypothermia with a presentation of standard strategy of sampling and analyses
  7. Long non-coding RNA-mediated regulation of signaling pathways in gastric cancer
  8. Opinion Paper
  9. Long story short: an introduction to the short-term and longterm Six Sigma quality and its importance in laboratory medicine for the management of extra-analytical processes
  10. EFLM Paper
  11. The European Federation of Clinical Chemistry and Laboratory Medicine syllabus for postgraduate education and training for Specialists in Laboratory Medicine: version 5 – 2018
  12. General Clinical Chemistry and Laboratory Medicine
  13. Early availability of laboratory results increases same day ward discharge rates
  14. Evaluation of the clinical implementation of a large-scale online e-learning program on venous blood specimen collection guideline practices
  15. Improved prospective risk analysis for clinical laboratories compensated for the throughput in processes
  16. National surveys on internal quality control for blood gas analysis and related electrolytes in clinical laboratories of China
  17. Clinical validation of S100B in the management of a mild traumatic brain injury: issues from an interventional cohort of 1449 adult patients
  18. A quantitative LC-MS/MS method for insulin-like growth factor 1 in human plasma
  19. Development and validation of a mass spectrometry-based assay for quantification of insulin-like factor 3 in human serum
  20. Anti-ganglioside antibodies: experience from the Italian Association of Neuroimmunology external quality assessment scheme
  21. Reference Values and Biological Variations
  22. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability
  23. Establishing normal values of total testosterone in adult healthy men by the use of four immunometric methods and liquid chromatography-mass spectrometry
  24. Cancer Diagnostics
  25. Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases
  26. Cardiovascular Diseases
  27. Prognostic implications of detectable cardiac troponin I below the 99th percentile in patients admitted to an emergency department without acute coronary syndrome
  28. Osteocalcin value to identify subclinical atherosclerosis over atherosclerotic cardiovascular disease (ASCVD) risk score in middle-aged and elderly Chinese asymptomatic men
  29. Infectious Diseases
  30. Comparison of four methods of establishing control limits for monitoring quality controls in infectious disease serology testing
  31. Letter to the Editor
  32. Letter to the Editor relative to Clin Chem Lab Med 2018;56(3):360–372
  33. Update in diagnosis and management of primary aldosteronism: reply to a Letter to the Editor
  34. Can calculated total nitrogen replace Kjeldahl total nitrogen measurements in 24-h urine samples?
  35. Analytical performance of the single well titer function of NOVA View®: good enough to omit ANA IIF titer analysis?
  36. Assessment of Architect cSystems Abbott® for the colorimetric measurement of lithium in urines and dyalisates
  37. β-Trace protein in hemodialysis – comparison of different therapy modalities and high flux dialyzers
  38. Orbitrap™ high-resolution mass spectrometry for the identification of amoxicillin crystalluria
  39. High fluorescence cell count in ascitic body fluids for carcinomatosis screening
  40. The International Society for Enzymology: a glorious history, a golden legacy
  41. Congress Abstracts
  42. 10th National Congress of the Portuguese Society of Clinical Chemistry, Genetics and Laboratory Medicine
  43. 5th EFLM-UEMS European Joint Congress in Laboratory Medicine
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 22.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2018-0134/html?lang=de
Button zum nach oben scrollen